Find, Fight and FollowTM .
Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to identify, target and treat cancer. Our pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095); (2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis tools. Our first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant. Progenics Pharmaceuticals, Inc. was incorporated in the State of Delaware in 1986.
We plan to further our mission by acquiring and developing oncology assets – companies and/or product candidates – that expand and complement our capabilities in the cancer space. Product candidates outside our core focus will continue to be out-licensed or partnered with motivated drug developers.